Acipimox - Pfizer

Drug Profile

Acipimox - Pfizer

Alternative Names: Olbetam

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antihyperlipidaemics; Carboxylic acids; Pyrazines
  • Mechanism of Action Adenosine deaminase inhibitors; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipidaemia; Hyperlipoproteinaemia type IIb; Hyperlipoproteinaemia type IV

Most Recent Events

  • 20 Nov 2017 Chemical structure added
  • 08 Aug 2017 Launched for Hyperlipidaemia in Hong Kong, New Zealand (PO) before August 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top